How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials

BACKGROUND AND OBJECTIVE: The use of valid surrogate endpoints can accelerate the development of phase III trials. Numerous validation methods have been proposed with the most popular used in a context of meta-analyses, based on a two-step analysis strategy. For two failure time endpoints, two assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofeu, Casimir Ledoux, Rondeau, Virginie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986733/
https://www.ncbi.nlm.nih.gov/pubmed/31990928
http://dx.doi.org/10.1371/journal.pone.0228098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986733/
https://www.ncbi.nlm.nih.gov/pubmed/31990928
http://dx.doi.org/10.1371/journal.pone.0228098

Ejemplares similares